Advancements in NAST, such as human epidermal growth factor receptor 2 (HER2)-targeted therapy or immune-check point blockade, have increased the pathologic complete response (pCR) rate, even in patients with locally advanced breast cancer [4–6]. This evidence concerns the gene ERBB2 and breast cancer.